𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Das inguinale Rezidiv nach therapeutischer Lymphadenektomie beim malignen Melanom

✍ Scribed by L. Kretschmer; C. Lautenschläger; K. -P. Preulβr; H. Fiedler


Publisher
Springer
Year
1993
Tongue
English
Weight
661 KB
Volume
378
Category
Article
ISSN
1435-2451

No coin nor oath required. For personal study only.

✦ Synopsis


In a retrospective study, 73 stage-II melanoma patients with 22 superficial and 51 deep groin dissections were observed over a maximum of 9 years of follow up (median 67.5 months). The 5-year survival rate of 29.8 % was consistent with that yielded by comparable analyses of other investigators. However, the probability of recurrence in the node dissection field was as high as 35%. All groin recurrences occurred in the first 29 months after lymph node clearance (median 6 months). Patients with groin recurrence following lymph-node dissection had a poor prognosis (median survival 12 months). In a multifactorial analysis (Cox model), the only prognostic factor of probability of recurrence was the development of regional in-transit cutaneous metastases (p = 0.0028). Factors that did not affect the appearance of recurrent metastases in the node dissection field were: site of primary melanoma, tumor thickness, epidermal ulceration, degree of lymph node involvement (p = 0.2) age, sex, degree of surgery (superficial or deep groin dissection) and adjuvant chemotherapy. Because regional in-transit cutaneous metastases mostly occur synchronously with groin recurrence or later, they are a typical concomitant phenomenon rather than a prognostic factor of recurrence.


📜 SIMILAR VOLUMES


Das axilläre Rezidiv nach Lymphadenektom
✍ L. Kretschmer; Ch. Lautenschläger; K. -P. Preusser; H. Fiedler; I. Hetschko 📂 Article 📅 1993 🏛 Springer 🌐 English ⚖ 802 KB

In a retrospective study 143 patients with 155 axillary lymphadenectomies were observed with a maximum of 8 years of follow-up (mean 51.9 +/- 25.8 months). At the time of their lymphadenectomies, 39 patients had histologically negative nodes (stage I), 85 patients lymph-node metastases (stage II), 1